{"id":"ngenla-somatrogon","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"DEVICE BREAKAGE","source":"FDA FAERS","actionTaken":"Reported 1 times"},{"date":"","signal":"HALLUCINATION","source":"FDA FAERS","actionTaken":"Reported 1 times"}],"drugInteractions":[{"drug":"Insulin","action":"Monitor","effect":"Increased risk of hypoglycemia"},{"drug":"Oral hypoglycemic agents","action":"Monitor","effect":"Increased risk of hypoglycemia"},{"drug":"Thiazide diuretics","action":"Monitor","effect":"Increased risk of hypokalemia"},{"drug":"Beta-blockers","action":"Monitor","effect":"Masked symptoms of hypoglycemia"},{"drug":"Glucocorticoids","action":"Monitor","effect":"Increased risk of hypokalemia"},{"drug":"Other growth hormone-releasing agents","action":"Avoid","effect":"Increased risk of adverse reactions"}],"commonSideEffects":[],"contraindications":["• Acute critical illness (4).\n• Hypersensitivity to somatrogon-ghla or excipients (4).\n• Closed epiphyses (4).\n• Active malignancy (4).\n• Active proliferative or severe non-proliferative diabetic retinopathy (4).\n• Prader-Willi syndrome who are severely obese or have severe respiratory impairment (4)."],"specialPopulations":{"Pregnancy":"NGENLA is not known if NGENLA will harm your child’s unborn baby. Talk to your child’s healthcare provider if your child is pregnant or plans to become pregnant.","Geriatric use":"text","Paediatric use":"NGENLA is a prescription medicine that contains a form of human growth hormone, like the growth hormone made by the human body, for children 3 years of age and older who are not growing because of low or no growth hormone levels.","Renal impairment":"text","Hepatic impairment":"text"}},"trials":[],"_chembl":null,"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=ngenla-somatrogon","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:57:18.835408+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:57:25.568791+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:57:18.854215+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ngenla-somatrogon","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:57:26.342316+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Growth hormone receptor agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:57:26.881187+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4297830/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:57:26.792786+00:00"}},"allNames":"ngenla (somatrogon)","offLabel":[],"timeline":[],"_dailymed":null,"aiSummary":"NGENLA (Somatrogon) is an investigational long-acting recombinant human growth hormone developed by Pfizer for the treatment of growth hormone deficiency in children. It aims to reduce the frequency of injections compared to daily growth hormone treatments. The drug has not yet received FDA approval and is currently in clinical trials. Preliminary data suggest that it may offer comparable efficacy to existing treatments with a more convenient dosing schedule. However, the safety profile and long-term outcomes are still under evaluation.","brandName":"NGENLA (Somatrogon)","ecosystem":[],"isGeneric":true,"mechanism":{"target":"Growth hormone receptor","novelty":"Long-acting formulation","modality":"Protein fusion","drugClass":"Recombinant human growth hormone","explanation":"","oneSentence":"","technicalDetail":"The drug consists of a recombinant human growth hormone (rhGH) fused to a protein domain from albumin, which enhances its stability and prolongs its circulation time in the bloodstream."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"_scrapedAt":"2026-03-27T23:28:42.778Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"commercial":{"yoyGrowth":"7%","launchDate":null,"annualCostUS":"$9,684/yr","genericStatus":"Generic — off-patent","currentRevenue":"","patientPopulation":"Children with growth hormone deficiency","peakSalesEstimate":""},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=ngenla-somatrogon","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ngenla-somatrogon","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://open.fda.gov/apis/drug/event/","fields":["safetySignals"],"source":"FDA FAERS"},{"id":5,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":6,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:57:28.662141+00:00","fieldsConflicting":2,"overallConfidence":0.8},"_whoChecked":true,"biosimilars":[],"competitors":["Genotropin (Pfizer)","Norditropin (Novo Nordisk)","Humatrope (Eli Lilly)"],"genericName":"ngenla-somatrogon","indications":{"approved":[{"name":"Idiopathic short stature in pediatric patients 2 years of age and older","regulator":"FDA"},{"name":"Short stature associated with Turner syndrome in pediatric patients 2 years of age and older","regulator":"FDA"},{"name":"Short stature associated with SHOX deficiency in pediatric patients 2 years of age and older","regulator":"FDA"},{"name":"Short stature associated with idiopathic growth hormone deficiency in pediatric patients 2 years of age and older","regulator":"FDA"},{"name":"Short stature associated with other causes of growth hormone deficiency in pediatric patients 2 years of age and older","regulator":"FDA"}],"offLabel":[],"pipeline":["Growth hormone deficiency in children"]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07226089","phase":"PHASE3","title":"Comparison of Weekly Somatrogon to Daily Genotropin in Children Born Small for Gestational Age or With Idiopathic Short Stature.","status":"RECRUITING","sponsor":"Rabin Medical Center","startDate":"2026-02","conditions":"ISS, SGA","enrollment":254},{"nctId":"NCT05509894","phase":"","title":"Korean Post-marketing Surveillance Ngenla® Pre-filled Pen Injection for the Treatment of Pediatric Patients With Growth Disturbance Due to Insufficient Secretion of Growth Hormone","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-06-20","conditions":"Pediatric Growth Hormone Deficiency","enrollment":565},{"nctId":"NCT05602766","phase":"","title":"Ngenla Subcutaneous Injection Special Investigation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2023-02-06","conditions":"Growth Hormone Deficiency Without Epiphyseal Closure","enrollment":1}],"_emaApprovals":[{"date":"","name":"NGENLA (Somatrogon)","status":"Authorised","regulator":"EMA"}],"_faersSignals":[{"count":1,"reaction":"DEVICE BREAKAGE"},{"count":1,"reaction":"HALLUCINATION"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"molecularData":{"oral":false,"chemblId":"CHEMBL4297830","moleculeType":"Protein","molecularWeight":""},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL4297830"},"formularyStatus":[],"_approvalHistory":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Hematology"],"biosimilarFilings":[],"recentPublications":[],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"Protein fusion","firstApprovalDate":"","enrichmentLevel":3,"visitCount":3,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"US","currency":"USD","price_amount":"9684.00","price_per":"year","price_type":"annual_list","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:57:28.662141+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}